Introduction
Methods
Number of centers responded | % | Avg. no of LGG per center and year | Range | |
---|---|---|---|---|
Country of practice | ||||
Germany | 40 | 31 | 20 | 5–50 |
Italy | 14 | 11 | 10 | 5–90 |
France | 9 | 6 | 25 | 3–100 |
Switzerland | 8 | 7 | 20 | 5–100 |
United Kingdom | 8 | 6 | 30 | 10–60 |
Austria | 7 | 5 | 20 | 6–40 |
Spain | 7 | 5 | 5 | 3–20 |
Netherlands | 6 | 5 | 25 | 15–40 |
Portugal | 4 | 3 | 20 | 2–20 |
Belgium | 3 | 2 | 15 | 15–30 |
Greece | 3 | 2 | 25 | 10–30 |
Poland | 3 | 2 | 25 | 20–30 |
Czech Republic | 2 | 2 | 15 | 15 |
Russian Federation | 2 | 2 | 55 | 50–60 |
Serbia | 2 | 2 | 15 | 10–20 |
Sweden | 2 | 2 | 20 | 20 |
Bulgaria | 1 | < 1 | 10 | 10 |
Denmark | 1 | < 1 | 20 | 20 |
Hungary | 1 | < 1 | n/a | n/a |
Lithuania | 1 | < 1 | 30 | 30 |
Norway | 1 | < 1 | 30 | 30 |
Romania | 1 | < 1 | 10 | 10 |
Turkey | 1 | < 1 | 20 | 20 |
Ukraine | 1 | < 1 | 5 | 5 |
Use of 3T imaging | 128 | |||
Always | 29 | 22.8 | ||
If available | 59 | 46.5 | ||
Only 1.5T | 39 | 30.7 | ||
Identical MR scanner | ||||
Yes | 25 | 20.0 | ||
No | 24 | 19.2 | ||
Mostly yes | 72 | 57.6 | ||
Mostly no | 4 | 3.2 |
Total number of patients | ||||
---|---|---|---|---|
Slice thickness of T1 imaging (mm) | ||||
< 1.5 | 66 | 53.7 |
–
| 1585 |
1.6–3 | 44 | 35.8 |
–
| 781 |
> 3 | 13 | 10.6 |
–
| 356 |
Slice thickness of T2 imaging (mm) | ||||
< 1.5 | 40 | 32.8 |
–
| 1027 |
1.6–3 | 54 | 44.3 |
–
| 1133 |
> 3 | 28 | 23.0 |
–
| 542 |
Imaging intervals in relation to the amount of residual disease | ||||
No remnant (weeks) | ||||
< 12 | 3 | 2.4 | ||
12–24 | 87 | 68.5 | ||
> 24 | 15 | 11.8 | ||
52 | 4 | 3.1 | ||
< 10 ml remnant (weeks) | ||||
< 12 | 4 | 3.1 | ||
12–24 | 91 | 71.7 | ||
> 24 | 12 | 9.4 | ||
52 | 0 | 0.0 | ||
11–15 ml remnant (weeks) | ||||
< 12 | 4 | 3.1 | ||
12–24 | 95 | 74.8 | ||
> 24 | 9 | 7.1 | ||
52 | 0 | 0.0 | ||
> 15 ml remnant (weeks) | ||||
< 12 | 7 | 5.5 | ||
12–24 | 97 | 76.4 | ||
> 24 | 4 | 3.1 | ||
52 | 0 | 0.0 | ||
Unresectable LGG (weeks) | ||||
< 12 | 1 | 0.8 | ||
12–24 | 97 | 76.4 | ||
> 24 | 6 | 4.7 | ||
52 | 3 | 2.4 |
Results
Basic information
Physicians involved in treatment of DLGG
Imaging
Advanced imaging
n | % | |
---|---|---|
T1 + PWI + MRS | 23 | 18 |
T1 + FET-PET | 20 | 16 |
T1 + PWI | 20 | 16 |
T1 | 19 | 15 |
T1 + PWI + FET-PET | 10 | 8 |
T1 + PWI + MRS + FET-PET | 8 | 6 |
T1 + MRS | 4 | 3 |
T1 + MRS + FET-PET | 3 | 2 |
T1 + PWI + MRS + other | 3 | 2 |
FET-PET | 3 | 2 |
PWI + MRS | 3 | 2 |
T1 + PWI + other | 2 | 2 |
T1 + other | 2 | 2 |
other | 8 | 6 |
Other | ||
Biopsy/resection | 7 | 6 |
Evaluate changes in growth rate/volumetric expansion | 3 | 2 |
F-DOPA PET | 1 | 1 |
Arterial-spin labelling MRI | 1 | 1 |
DWI/ADC | 1 | 1 |